全球抗帕金森氏症药物市场：至2030年

全球抗帕金森氏症药物市场预计将从 2025 年的 61 亿美元成长到 2030 年底的 92 亿美元，2025 年至 2030 年的复合年增长率为 8.6%。

预计北美市场将从2025年的35亿美元成长到2030年底的55亿美元，预测期间的复合年增长率为9.5%。预计欧洲市场将从2025年的14亿美元成长到2030年底的20亿美元，预测期间的复合年增长率为8%。

本报告调查了全球抗帕金森氏症药物市场，并提供了市场概况、市场影响因素和市场机会分析、市场规模趋势和预测以及各个细分市场和地区的详细分析。

目录

第一章执行摘要

• 市场展望
• 调查范围
• 市场摘要
• 概述
• 当前市场状况
• 細項分析
• 新兴技术
• 结论

第二章 市场概述

• 概述和市场定义
• 病理学
• 症状
• 诊断
• 治疗和管理
• 宏观经济因素分析
• 人口因素
• 环境因素
• 地缘政治因素
• 经济因素
• 美国关税对抗帕金森氏症药物市场的影响
• 波特五力分析
• 供应链分析

第三章 市场动态

• 市场动态
• 市场驱动因素
• 帕金森氏症的盛行率
• 大量未满足需求带来创新
• 透过产业合作加速研发
• 增加公共和私人投资和支持
• 市场限制
• 抗帕金森氏症药物的副作用
• 药物研发高成本、成功率低
• 市场机会
• 新兴国家意识的增强
• 强大的管道

第四章：监理现状

• 抗帕金森氏症药物的监管问题
• 美国
• 欧洲
• 日本

第五章 新兴技术与发展

• 新兴技术
• 药物和医疗设备组合
• 细胞和基因治疗
• 疫苗
• 单株抗体
• 其他联合治疗
• 管道分析
• 关键要点

第六章市场区隔分析

• 概述
• 关键要点
• 细分市场
• 按药品类别进行市场分析
• 多巴胺促效剂
• 多巴胺促效剂
• 儿茶酚甲基转移酵素抑制剂
• 单胺氧化酵素B抑制剂
• 抗胆碱药物
• 其他的
• 地理分布
• 各地区市场分析
• 关键要点
• 北美洲
• 欧洲
• 亚太地区
• 其他地区

第七章 竞争讯息

• 关键要点
• 市场占有率分析
• 策略倡议
• 协议、合作与伙伴关係
• 获得

第八章全球抗帕金森氏症药物市场的永续性：ESG 视角

• ESG：简介
• 永续性趋势和倡议
• 环境
• 社会与管治倡议
• ESG风险评估
• 结论

第九章 附录

• 调查方法
• 来源
• 简称
• 公司简介
• ABBVIE INC.
• ACADIA PHARMACEUTICALS INC.
• AMNEAL PHARMACEUTICALS LLC.
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• F. HOFFMANN-LA ROCHE LTD.
• H. LUNDBECK A/S
• KYOWA KIRIN CO. LTD.
• MERZ THERAPEUTICS
• NEUROCRINE BIOSCIENCES INC.
• NEURODERM
• NEWRON PHARMACEUTICALS SPA
• NOVARTIS AG
• PFIZER INC.
• SUPERNUS PHARMACEUTICALS INC.
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• 新兴Start-Ups/市场颠覆者

The global market for anti-Parkinson’s drugs is projected to grow from $6.1 billion in 2025 to reach $9.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030.

The North American market for anti-Parkinson’s drugs is projected to grow from $3.5 billion in 2025 to reach $5.5 billion by the end of 2030, at a CAGR of 9.5% from 2025 to 2030.

The European market for anti-Parkinson’s drugs is projected to grow from $1.4 billion in 2025 to reach $2.0 billion by the end of 2030, at a CAGR of 8% from 2025 to 2030.

Report Scope

The report provides an overview of the global anti-Parkinson's drugs market and analyzes market trends. It includes global revenue ($ millions) for the base year data of 2024, estimated data for 2025 and forecast of compound annual growth rates (CAGRs) from 2025 to 2030. The market is segmented by drug class (based on mechanisms of action) and regions. By drug class, the market is segmented into dopaminergic, dopamine agonists, catechol-O-methyltransferase (COMT) inhibitors, monoamine oxidase-B (MAO-B) inhibitors, anticholinergic and others. The regions covered in this study are North America, Europe, Asia-Pacific, the Middle East and Africa, and South America, focusing on the major countries in these regions. The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe. Asia-Pacific includes China, Japan, India, South Korea, Australia and the Rest of Asia-Pacific. The report focuses on the driving trends and challenges affecting the market. It analyzes corporate environmental, social and governance (ESG) developments and discusses emerging technologies related to the market. The report also includes an analysis of the competitive landscape and company profiles that address such details as overview, key financials, product portfolio and recent developments of key market businesses.

Report Includes

• 46 data tables and 55 additional tables
• An overview of the global market for anti-Parkinson's drugs
• In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, forecasts for 2030 and projections of compound annual growth rates (CAGRs) through 2030
• Evaluation of the current market size and revenue growth prospects specific to anti-Parkinson's drugs, accompanied by a market share analysis by drug class and region
• Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, regulatory framework and reimbursement scenarios, and ESG trends in the market
• Insights derived from Porter's Five Forces model, global value chain and case studies
• Patent analysis and emerging trends and developments in patent activity
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
• Identification of companies best positioned to meet this demand due to their proprietary technologies, M&As, joint ventures and other strategic alliances
• Descriptive profiles of leading companies, including AbbVie Inc., Amneal Pharmaceuticals LLC., Acadia Pharmaceuticals Inc., Supernus Pharmaceuticals Inc., and Teva Pharmaceutical Industries Co. Ltd.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Overview
• Current Market Scenario
• Segmental Analysis
• Emerging Technologies
• Conclusion

Chapter 2 Market Overview

• Overview and Market Definition
• Pathophysiology
• Symptoms
• Diagnosis
• Treatment and Management
• Macroeconomic Factors Analysis
• Demographic Factors
• Environmental Factors
• Geopolitical Factors
• Economic Factors
• Impact of U.S. Tariffs on the Anti-Parkinson's Drugs Market
• Porter's Five Forces Analysis
• Potential for New Entrants (Low to Moderate)
• Bargaining Power of Suppliers (Moderate to High)
• Bargaining Power of Buyers (Moderate)
• Threat of Substitute Products or Services (Moderate to High)
• Industry Rivalry (High)
• Supply Chain Analysis
• Research and Development (R&D)
• Manufacturing
• Packaging
• Wholesale Distributors and Repackagers
• Pharmacies
• Dispensed to Consumers

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Prevalence of Parkinson's Disease
• High Unmet Treatment Need Leads to Innovation
• Industry Collaborations Accelerate R&D
• Increased Public and Private Investments and Support
• Market Restraints
• Adverse Effects Associated with Anti-Parkinson's Drugs
• High Cost of Drug Development and Low Success Rate
• Market Opportunities
• Increased Awareness in Emerging Countries
• Robust Pipeline

Chapter 4 Regulatory Landscape

• Regulatory Aspects of Anti-Parkinson's Drugs
• United States
• Europe
• Japan

Chapter 5 Emerging Technologies and Developments

• Emerging Technologies
• Drug-Device Combinations
• Cell and Gene Therapies
• Vaccine
• Monoclonal Antibodies
• Other Combination Therapies
• Pipeline Analysis
• Key Takeaways

Chapter 6 Market Segmentation Analysis

• Overview
• Key Takeaways
• Segmentation Breakdown
• Market Analysis by Drug Class
• Dopaminergic
• Dopamine Agonists
• Catechol-O-methyl Transferase Inhibitors
• Monoamine Oxidase B Inhibitors
• Anticholinergics
• Others
• Geographic Breakdown
• Market Analysis by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Key Takeaways
• Market Share Analysis
• Strategic Initiatives
• Agreements, Collaborations and Partnerships
• Acquisitions

Chapter 8 Sustainability in the Anti-Parkinson's Drugs Global Market: An ESG Perspective

• Introduction to ESG
• Sustainability Trends and Initiatives
• Environmental
• Social and Governance Initiatives
• ESG Risk Ratings
• Concluding Remarks

Chapter 9 Appendix

• Research Methodology
• Sources
• Abbreviations
• Company Profiles
• ABBVIE INC.
• ACADIA PHARMACEUTICALS INC.
• AMNEAL PHARMACEUTICALS LLC.
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• F. HOFFMANN-LA ROCHE LTD.
• H. LUNDBECK A/S
• KYOWA KIRIN CO. LTD.
• MERZ THERAPEUTICS
• NEUROCRINE BIOSCIENCES INC.
• NEURODERM
• NEWRON PHARMACEUTICALS SPA
• NOVARTIS AG
• PFIZER INC.
• SUPERNUS PHARMACEUTICALS INC.
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• Emerging Start-ups/Market Disruptors

List of Tables

• Summary Table : Global Market for Anti-Parkinson's Drugs, by Region, Through 2030
• Table 1 : NIH Funding Estimates for Parkinson's Disease Research, 2019-2024
• Table 2 : Selected List of Anti-Parkinson's Drugs in Clinical Trials
• Table 3 : Global Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 4 : Global Market for Dopaminergic Drugs, by Region, Through 2030
• Table 5 : Classification of Dopamine Agonists
• Table 6 : Global Market for Dopamine Agonist Drugs, by Region, Through 2030
• Table 7 : Global Market for Catechol-O-Methyl Transferase (COMT) Inhibitor Drugs, by Region, Through 2030
• Table 8 : Global Market for Monoamine Oxidase B (MAO-B) Inhibitor Drugs, by Region, Through 2030
• Table 9 : Global Market for Anticholinergic Drugs, by Region, Through 2030
• Table 10 : List of Other Common Drugs
• Table 11 : Global Market for Other Anti-Parkinson's Drugs, by Region, Through 2030
• Table 12 : Global Market for Anti-Parkinson's Drugs, by Region, Through 2030
• Table 13 : North American Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 14 : North American Market for Anti-Parkinson's Drugs, by Country, Through 2030
• Table 15 : U.S. Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 16 : Canadian Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 17 : Mexican Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 18 : European Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 19 : European Market for Anti-Parkinson's Drugs, by Country, Through 2030
• Table 20 : German Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 21 : U.K Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 22 : French Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 23 : Spanish Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 24 : Italian Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 25 : Rest of Europe Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 26 : Asia-Pacific Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 27 : Asia-Pacific Market for Anti-Parkinson's Drugs, by Country, Through 2030
• Table 28 : Chinese Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 29 : Japanese Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 30 : Indian Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 31 : South Korean Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 32 : Australian Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 33 : Rest of Asia-Pacific Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 34 : RoW Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 35 : RoW Market for Anti-Parkinson's Drugs, by Country, Through 2030
• Table 36 : Agreements, Collaborations and Partnerships in the Anti-Parkinson's Drugs Market, 2021-2025
• Table 37 : Acquisitions in the Anti-Parkinson's Drugs Market, 2021-2024
• Table 38 : Environmental Initiatives by Various Anti-Parkinson's Drugs Manufacturers
• Table 39 : Key Social and Governance Issues in Anti-Parkinson's Drugs Market
• Table 40 : ESG Risk Rankings for Anti-Parkinson's Drugs Companies, 2024
• Table 41 : Information Sources in this Report
• Table 42 : Abbreviations Used in the Global Anti-Parkinson's Drugs Market
• Table 43 : AbbVie Inc.: Company Snapshot
• Table 44 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
• Table 45 : AbbVie Inc.: Product Portfolio
• Table 46 : AbbVie Inc.: News/Key Developments, 2023 and 2024
• Table 47 : Acadia Pharmaceuticals Inc.: Company Snapshot
• Table 48 : Acadia Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
• Table 49 : Acadia Pharmaceuticals Inc.: Product Portfolio
• Table 50 : Acadia Pharmaceuticals Inc.: News/Key Developments, 2022-2024
• Table 51 : Amneal Pharmaceuticals LLC.: Company Snapshot
• Table 52 : Amneal Pharmaceuticals LLC.: Financial Performance, FY 2023 and 2024
• Table 53 : Amneal Pharmaceuticals LLC.: Product Portfolio
• Table 54 : Amneal Pharmaceuticals LLC.: News/Key Developments, 2023 and 2024
• Table 55 : Boehringer Ingelheim International GmbH: Company Snapshot
• Table 56 : Boehringer Ingelheim International GmbH: Financial Performance, FY 2023 and 2024
• Table 57 : Boehringer Ingelheim International GmbH: Product Portfolio
• Table 58 : Boehringer Ingelheim International GmbH: News/Key Developments, 2024 and 2025
• Table 59 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 60 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
• Table 61 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 62 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024
• Table 63 : H. Lundbeck A/S: Company Snapshot
• Table 64 : H. Lundbeck A/S: Financial Performance, FY 2023 and 2024
• Table 65 : H. Lundbeck A/S: Product Portfolio
• Table 66 : H. Lundbeck A/S: News/Key Developments, 2021-2024
• Table 67 : Kyowa Kirin Co. Ltd.: Company Snapshot
• Table 68 : Kyowa Kirin Co. Ltd.: Financial Performance, FY 2023 and 2024
• Table 69 : Kyowa Kirin Co. Ltd.: Product Portfolio
• Table 70 : Kyowa Kirin Co. Ltd.: News/Key Developments, 2022
• Table 71 : Merz Therapeutics: Company Snapshot
• Table 72 : Merz Therapeutics: Product Portfolio
• Table 73 : Merz Therapeutics: News/Key Developments, 2024
• Table 74 : Neurocrine Biosciences Inc.: Company Snapshot
• Table 75 : Neurocrine Biosciences Inc.: Financial Performance, FY 2023 and 2024
• Table 76 : Neurocrine Biosciences Inc.: Product Portfolio
• Table 77 : Neurocrine Biosciences Inc.: News/Key Developments, 2023
• Table 78 : NeuroDerm: Company Snapshot
• Table 79 : NeuroDerm: Product Portfolio
• Table 80 : NeuroDerm: News/Key Developments, 2024 and 2025
• Table 81 : Newron Pharmaceuticals SpA: Company Snapshot
• Table 82 : Newron Pharmaceuticals SpA: Financial Performance, FY 2023 and 2024
• Table 83 : Newron Pharmaceuticals SpA: Product Portfolio
• Table 84 : Newron Pharmaceuticals SpA: News/Key Developments, 2021
• Table 85 : Novartis AG: Company Snapshot
• Table 86 : Novartis AG: Financial Performance, FY 2023 and 2024
• Table 87 : Novartis AG: Product Portfolio
• Table 88 : Novartis AG: News/Key Developments, 2021-2024
• Table 89 : Pfizer Inc.: Company Snapshot
• Table 90 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
• Table 91 : Pfizer Inc.: Product Portfolio
• Table 92 : Supernus Pharmaceuticals Inc.: Company Snapshot
• Table 93 : Supernus Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
• Table 94 : Supernus Pharmaceuticals Inc.: Product Portfolio
• Table 95 : Supernus Pharmaceuticals Inc.: News/Key Developments, 2021-2025
• Table 96 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
• Table 97 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
• Table 98 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
• Table 99 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2021
• Table 100 : List of Few Emerging Startups in the Anti-Parkinson's Drugs Market

List of Figures

• Summary Figure : Global Market Shares of Anti-Parkinson's Drugs, by Region, 2024
• Figure 1 : Porter's Five Forces Analysis of the Anti-Parkinson's Drugs Market
• Figure 2 : Supply Chain Process of Pharmaceutical Drugs
• Figure 3 : Market Dynamics of Anti-Parkinson's Drugs
• Figure 4 : Clinical Trial Analysis, as of April 2025
• Figure 5 : Number of Active PD Drug Trials, by Phase and Categories, 2024
• Figure 6 : Global Market Shares of Anti-Parkinson's Drugs, by Drug Class, 2024
• Figure 7 : Global Market Shares of Anti-Parkinson's Drugs, by Region, 2024
• Figure 8 : North American Market Shares of Anti-Parkinson's Drugs, by Country, 2024
• Figure 9 : European Market Shares of Anti-Parkinson's Drugs, by Country, 2024
• Figure 10 : Asia-Pacific Market Shares of Anti-Parkinson's Drugs, by Country, 2024
• Figure 11 : Global Market Shares of Anti-Parkinson's Drugs, by Key Companies, 2024
• Figure 12 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 13 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 14 : Acadia Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 15 : Amneal Pharmaceuticals LLC.: Revenue Share, by Business Unit, FY 2024
• Figure 16 : Boehringer Ingelheim International GmbH: Revenue Share, by Business Unit,FY 2024
• Figure 17 : Boehringer Ingelheim International GmbH: Revenue Share, by Region/Country,FY 2024
• Figure 18 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
• Figure 19 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
• Figure 20 : H. Lundbeck A/S: Revenue Share, by Business Unit, FY 2024
• Figure 21 : H. Lundbeck A/S: Revenue Share, by Country/Region, FY 2024
• Figure 22 : Kyowa Kirin Co. Ltd.: Revenue Share by Country/Region, FY 2024
• Figure 23 : Neurocrine Biosciences Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 24 : Newron Pharmaceuticals SpA: Revenue Share, by Business Unit, FY 2024
• Figure 25 : Novartis AG: Revenue Share, by Business Unit, FY 2024
• Figure 26 : Novartis AG: Revenue Share, by Country/Region, FY 2024
• Figure 27 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 28 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 29 : Supernus Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 30 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Business Unit, 2024